Skip to main content
    O

    Organogenesis Holdings Inc (ORGO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.81
    +0.01 (+1.06%)

    Market Cap: $104.24M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Organogenesis Holdings Inc (ORGO) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Organogenesis Holdings (ORGO) has a market cap of $104.24M and an enterprise value of $93.29M. It kept -38.45% of revenue as net income over the last 12 months. Revenue fell 24.33% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 10.51% below the market cap, as cash exceeds debt.

    Market Cap$104.24M
    Enterprise Value$93.29M
    Latest price (Nov 17, 2026)$0.81

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.25% in the quarter ended Sep 30, 2026 and shrank 1.36% a year over 2 years.

    Shares Outstanding128.99M
    Shares Change (YoY)+1.66%
    Shares Change (QoQ)+0.25%
    Share Count Growth (2Y CAGR)-1.36%

    Valuation Ratios

    Sales and book value multiples are 0.3x and 0.9x. Its year-end P/S ranged from 0.8x to 2.6x from 2019 to 2025.

    P/S Ratio0.3x
    Forward P/S0.6x
    P/B Ratio0.9x
    P/TBV Ratio1.2x
    P/OCF Ratio10.1x

    Valuation history and multiples

    Price Statistics

    The stock is down 86.70% over 52 weeks and trades 29.57% below its 50-day average.

    Beta (1Y)1.23
    52-Week Change-86.70%
    1-Month Change-20.43%
    3-Month Change-57.51%
    6-Month Change-66.60%
    5-Year Change-93.00%
    Total Return (1Y)-86.70%
    Total Return (3Y CAGR)-32.59%
    Total Return (5Y CAGR)-39.35%
    Max Drawdown (1Y)-87.39%
    Max Drawdown (3Y)-88.45%
    Sharpe Ratio (1Y)-2.80
    Correlation with SPY (1Y)0.25
    50-Day Average$1.15
    200-Day Average$2.19
    52-Week Range$0.73 to $5.91
    RSI (14 Days)37.7
    Average Volume (20 Days)1.13M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.32x current liabilities, and total debt is 0.09x shareholder equity.

    Current Ratio3.32x
    Quick Ratio2.76x
    Debt / Equity0.09x
    Interest Coverage-19.59x

    Returns and Efficiency

    Return on invested capital is -66.28% over the last 12 months, against a 5-year average of 8.08%.

    Return on Equity (ROE)-113.04%
    Return on Assets (ROA)-36.69%
    Return on Invested Capital (ROIC)-66.28%
    ROE (5Y Average)11.86%
    ROA (5Y Average)6.43%
    ROIC (5Y Average)8.08%
    Asset Turnover0.80x
    Inventory Turnover4.33x
    Receivables Turnover3.64x
    Cash Conversion Cycle107 days

    Scores

    ORGO has an Altman Z-Score of 0.44, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score0.44
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $352.05M over the last 12 months.

    Revenue$352.05M
    Revenue Growth (YoY)-24.33%
    Gross Profit$230.79M
    Operating Income-$86.08M
    Pretax Income-$85.55M
    Net Income-$135.35M
    EBITDA-$63.03M
    Reported EPS (TTM)-$0.99

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 32.46% of the $368.90M in total assets.

    Cash and Equivalents$21.33M
    Total Debt$10.37M
    Net Cash$10.95M
    Net Cash Per Share$0.08
    Working Capital$110.48M
    Shareholder Equity$119.74M
    Book Value Per Share$0.93
    Tangible Book Value$88.39M
    Tangible Book Per Share$0.69
    Total Assets$368.90M
    Total Liabilities$106.16M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $10.36M of capital spending, operating cash flow left -$64.00K of free cash flow.

    Operating Cash Flow$10.30M
    Capital Expenditures$10.36M
    Free Cash Flow-$64.00K
    FCF Per Share$0.00
    Depreciation and Amortization$23.21M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -24.45%, against a 5-year average of 6.19%.

    Gross Margin65.56%
    Operating Margin-24.45%
    Pretax Margin-24.30%
    Net Margin-38.45%
    EBITDA Margin-17.90%
    FCF Margin-0.02%
    Gross Margin (5Y Average)75.86%
    Operating Margin (5Y Average)6.19%
    Net Margin (5Y Average)6.30%

    Growth

    Revenue grew 7.76% a year over 3 years, and EPS 17.43% a year.

    Revenue Growth (3Y CAGR)+7.76%
    Revenue Growth (5Y CAGR)+10.77%
    EPS Growth (3Y CAGR)+17.43%
    EPS Growth (5Y CAGR)+17.41%
    Operating Income Growth (3Y CAGR)+26.07%
    Book Value Per Share Growth (2Y CAGR)+3.64%
    Tangible Book Per Share Growth (2Y CAGR)+5.71%

    Revenue and profit by year

    Dividends and Yields

    ORGO does not pay a dividend. Its free cash flow yield is -0.06%.

    FCF Yield-0.06%
    Shareholder Yield0.00%

    Peer Position

    Against 7 similar companies, ORGO has the lowest P/S.

    P/S Ratio0.3x vs 1.4x median
    ROIC-66.28% vs -11.66% median
    Revenue Growth (Trailing 4 Quarters, YoY)-24.33% vs +10.06% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -35.51% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-35.51%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ORGO

    What is ORGO's market cap?

    Organogenesis Holdings has a market cap of $104.24M. Its enterprise value, which adds debt and subtracts cash, is $93.29M.

    How many shares of ORGO are outstanding?

    Organogenesis Holdings has 128.99M shares outstanding. The count is up 1.66% from a year earlier.

    Does ORGO pay a dividend?

    No. Organogenesis Holdings does not pay a dividend.

    How much debt does ORGO have?

    Organogenesis Holdings has $10.37M of total debt and $21.33M of cash and equivalents, a net cash position of $10.95M.